News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hutchison Medipharma Starts Clinical Trial on Fourth Cancer Drug


11/2/2012 2:49:58 PM

November 2, 2012 -- Hutchison MediPharma, the drug discovery arm of China MediTech, has begun a Phase I clinical trial of Theliatinib (HMPL-309) in patients with non-small cell lung cancer. The drug is a small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase. Unlike most EGFR inhibitors, Theliatinib has shown efficacy against NSCLC that does not display EGFR-enabling mutations in pre-clinical testing, according to Chi-Med. More details....

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES